⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SLXN News
Silexion Therapeutics Corp Ordinary Shares
Form 8-K
sec.gov
SLXNW
SLXN
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXNW
SLXN
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
SLXN
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
globenewswire.com
SLXN
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
globenewswire.com
SLXN
Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026
globenewswire.com
SLXN
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
globenewswire.com
SLXN
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
globenewswire.com
SLXN
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference
globenewswire.com
SLXN